Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584691 | 1.00 | OXTR (0.36) | OXTRAVPR1AL3MBTL1KMT2AADRB3 | |
| SCHEMBL4584643 | 0.89 | OXTR (0.38) | OXTRAVPR1AL3MBTL1ADRB3ADRB1 | |
| SCHEMBL4584648 | 0.89 | OXTR (0.38) | OXTRAVPR1AL3MBTL1ADRB3ADRB1 | |
| SCHEMBL4584301 | 0.87 | OXTR (0.37) | OXTRAVPR1AL3MBTL1KMT2AADRB3 | |
| SCHEMBL4584305 | 0.87 | OXTR (0.37) | OXTRAVPR1AL3MBTL1KMT2AADRB3 | |
| SCHEMBL5703933 | 0.84 | OXTR (0.32) | OXTRAVPR1AADRB3ADRB1 | |
| SCHEMBL4584637 | 0.81 | L3MBTL1 (0.42) | L3MBTL1KMT2AADRB3ADRB1ABCB1 | |
| SCHEMBL4584644 | 0.81 | L3MBTL1 (0.42) | L3MBTL1KMT2AADRB3ADRB1ABCB1 | |
| SCHEMBL4584673 | 0.78 | PPARG (0.36) | OXTRAVPR1AADRB3ADRB1MGLL | |
| SCHEMBL5703931 | 0.78 | OXTR (0.33) | OXTRAVPR1AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | OXTR 196/4885AVPR1A 218/4885L3MBTL1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.